Biomea Fusion, Inc. (BMEA)
Nasdaq · Pharmaceutical Preparations · Inc. DE
What they're doing
Not enough recent activity to summarise.
Signals, last 12 months
- Insider purchaseHitchcock Michael J.M. (director) bought $99k of stock
- Material 8-K filingFiled 8-K disclosing material agreement
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | Erdtmann Rainer M | director | G | 50,600 | 0 | $0 |
| 2025-12-31 | Erdtmann Rainer M | director | G | 50,000 | 0 | $0 |
| 2025-12-31 | Erdtmann Rainer M | director | G | 50,000 | 0 | $0 |
| 2025-12-31 | Erdtmann Rainer M | director | G | 50,000 | 0 | $0 |
| 2025-12-31 | Erdtmann Rainer M | director | G | 50,000 | 0 | $0 |
| 2025-12-31 | Erdtmann Rainer M | director | G | 50,600 | 0 | $0 |
| 2025-12-11 | Erdtmann Rainer M | director | P | 30,000 | 1.43 | $42,900 |
| 2025-12-11 | Erdtmann Rainer M | director | P | 30,000 | 1.43 | $42,999 |
| 2025-12-02 | Hitchcock Michael J.M. | director | P | 100,000 | 0.99 | $99,000 |
| 2025-12-02 | Hitchcock Michael J.M. | director | P | 100,000 | 0.99 | $99,180 |
| 2025-12-01 | Erdtmann Rainer M | director | P | 10,000 | 1.05 | $10,500 |
| 2025-12-01 | Erdtmann Rainer M | director | P | 10,000 | 1.05 | $10,500 |
| 2025-11-28 | Erdtmann Rainer M | director | P | 40,000 | 1.1 | $44,000 |
| 2025-11-28 | Erdtmann Rainer M | director | P | 40,000 | 1.1 | $44,052 |
| 2025-01-31 | Erdtmann Rainer M | director | G | 10,000 | 0 | $0 |
| 2025-01-31 | Erdtmann Rainer M | director | G | 10,000 | 0 | $0 |
| 2025-01-31 | Erdtmann Rainer M | director | G | 10,000 | 0 | $0 |
| 2025-01-31 | Erdtmann Rainer M | director | G | 10,000 | 0 | $0 |
| 2025-01-31 | Erdtmann Rainer M | director | G | 10,000 | 0 | $0 |
| 2025-01-31 | Erdtmann Rainer M | director | G | 10,000 | 0 | $0 |
| 2025-01-31 | Erdtmann Rainer M | director | G | 10,000 | 0 | $0 |
| 2025-01-31 | Erdtmann Rainer M | director | G | 10,000 | 0 | $0 |
| 2025-01-31 | Erdtmann Rainer M | director | G | 10,000 | 0 | $0 |
| 2025-01-31 | Erdtmann Rainer M | director | G | 10,000 | 0 | $0 |
| 2025-01-31 | Erdtmann Rainer M | director | G | 10,000 | 0 | $0 |
| 2025-01-31 | Erdtmann Rainer M | director | G | 10,000 | 0 | $0 |
| 2025-01-28 | Erdtmann Rainer M | director | G | 40,000 | 0 | $0 |
| 2025-01-28 | Erdtmann Rainer M | director | G | 40,000 | 0 | $0 |
| 2024-11-30 | Valle Franco | officer | A | 495 | 6.15 | $3,044 |
| 2024-11-30 | Valle Franco | officer | A | 495 | 6.15 | $3,046 |
| 2024-09-30 | Hitchcock Michael J.M. | director | P | 10,000 | 10.06 | $100,600 |
| 2024-09-30 | Hitchcock Michael J.M. | director | P | 10,000 | 10.06 | $100,600 |
| 2024-06-11 | Valle Franco | officer | P | 12,509 | 4.43 | $55,361 |
| 2024-05-31 | Valle Franco | officer | A | 4,448 | 3.78 | $16,825 |
| 2024-05-31 | Frias Juan Pablo | officer | A | 349 | 8.94 | $3,121 |
| 2023-12-29 | Erdtmann Rainer M | director | G | 3,000 | 0 | $0 |
| 2023-12-29 | Erdtmann Rainer M | director | G | 3,000 | 0 | $0 |
| 2023-12-29 | Erdtmann Rainer M | director | G | 3,000 | 0 | $0 |
| 2023-12-29 | Erdtmann Rainer M | director | G | 3,000 | 0 | $0 |
| 2023-12-29 | Erdtmann Rainer M | director | G | 3,000 | 0 | $0 |
| 2023-12-29 | Erdtmann Rainer M | director | G | 3,000 | 0 | $0 |
| 2023-12-29 | Erdtmann Rainer M | director | G | 12,000 | 0 | $0 |
| 2023-11-30 | Valle Franco | officer | A | 1,345 | 3.78 | $5,087 |
| 2023-06-01 | A2A Pharmaceuticals, Inc. | ten percent owner | S | 50,000 | 34.56 | $1,728,165 |
| 2023-05-31 | Valle Franco | officer | A | 4,273 | 3.78 | $16,163 |
| 2023-05-31 | A2A Pharmaceuticals, Inc. | ten percent owner | S | 75,000 | 33.81 | $2,535,750 |
| 2023-05-12 | A2A Pharmaceuticals, Inc. | ten percent owner | S | 25,000 | 33.84 | $846,000 |
| 2023-05-09 | A2A Pharmaceuticals, Inc. | ten percent owner | S | 150,000 | 34.5 | $5,175,720 |
| 2023-05-08 | A2A Pharmaceuticals, Inc. | ten percent owner | S | 100,000 | 33.99 | $3,399,310 |
| 2023-04-20 | A2A Pharmaceuticals, Inc. | ten percent owner | S | 200,000 | 29.12 | $5,823,760 |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
No Wikipedia pageview data linked to this company.